Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:27 PM
Ignite Modification Date:
2025-12-24 @ 2:27 PM
NCT ID:
NCT02876159
Eligibility Criteria:
Inclusion Criteria:
* Capable of informed consent and provision of written informed consent before any study procedures.
* Capable of attending all study visits according to the study schedule.
* Are in good health, as determined by medical history and targeted physical exam related to this history.
* Oral temperature is less than 38 degrees Celsius.
* Resting pulse rate is between 50 and 115 beats per minute.
* Female subjects of childbearing age must have a negative urine pregnancy test within 24 hours before study vaccination.
* Have received the influenza vaccine at least 3 of the past 5 years or have received the influenza vaccine in 2 or less of the past 5 years.
Exclusion Criteria:
* Have an acute illness within 72 hours before vaccination.
* Have any condition that, in the opinion of the principal investigator, would place the subject at an unacceptable risk of injury or confound the interpretation of the study results.
* Have any acute or chronic medical condition that, in the opinion of the principal investigator, would make vaccination unsafe or interfere with the evaluation of immune response to study vaccination.
* Have a suppressed immune system as a result of illness, immunosuppressive medication, chemotherapy, or radiation therapy within 3 years prior to study vaccination.
* Have known HIV, hepatitis B, or hepatitis C infection.
* Have a known history of autoimmune disease.
* Have taken oral or parenteral corticosteroids of any dose within 30 days before study vaccination.
* Have taken high-dose inhaled corticosteroids within 30 days before study vaccination.
* Have received any licensed live vaccine within 30 days or any licensed inactivated vaccine within 14 days prior to study vaccination.
* Have planned vaccination with any vaccine during the 29-day duration of subject study participation.
* Have received immunoglobulin or other blood products, with the exception of Rho D immunoglobulin, within 90 days prior to study vaccination.
* Have donated blood or blood products within 30 days before study vaccination, plan to donate blood at any time during the 29-day duration of subject study participation, or plan to donate blood within 30 days after the last blood draw.
* Have known hypersensitivity or allergy to eggs, egg protein, chicken protein, or other compounds of the study vaccine.
* Have a history of severe reactions following vaccination with influenza virus vaccines
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
30 Years
Study:
NCT02876159
Study Brief:
Protocol Section:
NCT02876159